LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: EGPA: Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) as a special presentation of chronic rhinosinusitis with nasal polyps (CRSwNP).

    Hagemann, Jan / Laudien, Martin / Becker, Sven / Cuevas, Mandy / Klimek, Felix / Kianfar, Roya / Casper, Ingrid / Klimek, Ludger

    Allergologie select

    2024  Volume 8, Page(s) 18–25

    Abstract: Introduction: Eosinophilic granulomatosis with polyangiitis (EGPA) was formerly known as Churg-Strauss syndrome. The condition is characterized by disseminated necrotizing vasculitis with extravascular granulomas associated with hypereosinophilia. The ... ...

    Abstract Introduction: Eosinophilic granulomatosis with polyangiitis (EGPA) was formerly known as Churg-Strauss syndrome. The condition is characterized by disseminated necrotizing vasculitis with extravascular granulomas associated with hypereosinophilia. The vasculitides affect small vessels and are associated with antineutrophil cytoplasmic antibodies (ANCAs) detectable in the blood. Distinguishing between type 2-mediated chronic airway inflammation such as chronic rhinosinusitis with nasal polyps (CRSwNP) without vasculitis can be clinically challenging and should be considered.
    Materials and methods: Immunological background, diagnosis, and therapy of EGPA were identified through literature searches in Medline, PubMed, as well as national and international studies (ClinicalTrials.gov) and the Cochrane Library. Human studies published up to and including 10/2023 on the topic were considered.
    Results: In cases of deteriorating general health with previously known eosinophilic inflammation of the upper and lower airways, EGPA and its interdisciplinary investigation should be considered. Various types of eosinophilic inflammation and syndromes must be considered differentially.
    Conclusion: Characterization of mucosal airway inflammation through biomarker determination is meaningful and occasionally makes the difference for targeted therapy.
    Language English
    Publishing date 2024-03-21
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 2893503-2
    ISSN 2512-8957 ; 2512-8957
    ISSN (online) 2512-8957
    ISSN 2512-8957
    DOI 10.5414/ALX02475E
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Investigation of IL-2 and IFN-γ to EBV Peptides in Stimulated Whole Blood among Multiple Sclerosis Patients and Healthy Individuals.

    Rafiee, Nastaran / Ravanshad, Mehrdad / Asadi, Bahador / Kianfar, Roya / Maleki, Ali

    Intervirology

    2021  Volume 64, Issue 4, Page(s) 203–208

    Abstract: Introduction: Epstein-Barr virus (EBV), a double-stranded DNA virus, has 2 phases of lytic and latent infection in host cells. After infecting B lymphocytes, EBV becomes persistent in these cells. In healthy individuals, T lymphocytes play a key role in ...

    Abstract Introduction: Epstein-Barr virus (EBV), a double-stranded DNA virus, has 2 phases of lytic and latent infection in host cells. After infecting B lymphocytes, EBV becomes persistent in these cells. In healthy individuals, T lymphocytes play a key role in killing EBV-infected B cells. Statistical studies have shown that symptomatic EBV infection increases the risk of MS.
    Methods: This study intended to measure the immune system's response against the different components of EBV, focusing particularly on T lymphocytes' reaction. Consequently, the mRNA level of IL-2 and IFN-γ, liable for impressing autoimmune diseases and as indicators of T-cell function, was compared in EBNA1- and BRLF1-treated whole blood (WB) cultures of 10 healthy individuals and 10 MS patients using real-time RT-PCR.
    Results: The analysis of the results demonstrated a significant increased level of IL-2 in MS patients than healthy subjects after exposure to both peptides. Also, the mRNA level of IFN-γ increased in MS patients in EBNA1-treated WB culture.
    Conclusion: According to the study's results, EBV peptides can reactivate immune cells, especially T lymphocytes, and may indirectly induce inflammation and develop MS; however, it seems that long-time exposure to these peptides has reducing effect on T-cell function and faces the control of infected B lymphocytes with difficulties.
    MeSH term(s) Epstein-Barr Virus Infections ; Herpesvirus 4, Human ; Humans ; Interferon-gamma ; Interleukin-2 ; Multiple Sclerosis ; T-Lymphocytes
    Chemical Substances Interleukin-2 ; Interferon-gamma (82115-62-6)
    Language English
    Publishing date 2021-06-25
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 184545-7
    ISSN 1423-0100 ; 0300-5526
    ISSN (online) 1423-0100
    ISSN 0300-5526
    DOI 10.1159/000517002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1040: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Evaluation of IL-1β and IL-6 Expression following EBNA-1 and BRLF-1 Peptide Treatment in Epstein-Barr Virus-Positive Multiple Sclerosis Patients.

    Kianfar, Roya / Ravanshad, Mehrdad / Ghiass, Mohammad Adel / Rafiee, Nastaran / Shayeghpour, Ali / Maleki, Ali

    Intervirology

    2022  Volume 65, Issue 3, Page(s) 144–150

    Abstract: Introduction: Epstein-Barr virus (EBV/HHV-4) has been implicated in the pathogenesis of multiple sclerosis (MS). This study was conducted to investigate the levels of pro-inflammatory cytokines IL-1β and IL-6 in healthy EBV carriers and MS patients with ...

    Abstract Introduction: Epstein-Barr virus (EBV/HHV-4) has been implicated in the pathogenesis of multiple sclerosis (MS). This study was conducted to investigate the levels of pro-inflammatory cytokines IL-1β and IL-6 in healthy EBV carriers and MS patients with prior EBV infection in response to treatment with EBV nuclear antigen 1 (EBNA-1) and replication and transcription activator (BRLF-1/Rta) peptide antigens in whole blood cell culture to assess the cytokine expression across all cells in the peripheral blood.
    Methods: Isolated whole blood cells from the included participants were incubated at a concentration of 106 cells/mL with BRLF-1 or EBNA-1. The amount of IL-1β and IL-6 transcripts were measured with quantitative RT-PCR at day 3 after incubation. MTT assay was conducted to examine cytotoxicity of the peptides and their effect on cell viability. Changes in cytokine expression and cell viability were analyzed using one-way and two-way ANOVA, respectively.
    Results: Ten MS patients and ten healthy donors were enrolled in the study. Treatment with the peptide antigens resulted in increased cytokines expression in both MS patients and healthy subjects. Furthermore, IL-1β levels were higher in MS patients compared to healthy EBV carriers. MTT assay revealed no significant difference in cell viability between the two groups.
    Discussion: The higher levels of IL-1β in response to EBV antigens in MS patients may reflect the host neuroinflammatory environment and support the notion that immune response against EBV has a role as an aggravating factor in the progression of MS by contributing to the neuroinflammatory cascade.
    MeSH term(s) Cytokines/metabolism ; Epstein-Barr Virus Infections/complications ; Epstein-Barr Virus Nuclear Antigens/immunology ; Herpesvirus 4, Human ; Humans ; Immediate-Early Proteins/immunology ; Interleukin-1beta/metabolism ; Interleukin-6/metabolism ; Multiple Sclerosis/drug therapy ; Trans-Activators/immunology
    Chemical Substances BRLF1 protein, Human herpesvirus 4 ; Cytokines ; Epstein-Barr Virus Nuclear Antigens ; IL1B protein, human ; IL6 protein, human ; Immediate-Early Proteins ; Interleukin-1beta ; Interleukin-6 ; Trans-Activators ; EBV-encoded nuclear antigen 1 (O5GA75RST7)
    Language English
    Publishing date 2022-02-14
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 184545-7
    ISSN 1423-0100 ; 0300-5526
    ISSN (online) 1423-0100
    ISSN 0300-5526
    DOI 10.1159/000522577
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1040: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Hepatitis C virus DNA vaccines: a systematic review

    Shayeghpour, Ali / Kianfar, Roya / Hosseini, Parastoo / Ajorloo, Mehdi / Aghajanian, Sepehr / Hedayat Yaghoobi, Mojtaba / Hashempour, Tayebeh / Mozhgani, Sayed-Hamidreza

    Virology journal. 2021 Dec., v. 18, no. 1

    2021  

    Abstract: BACKGROUND: Vaccination against HCV is an effective measure in reduction of virus-related public health burden and mortality. However, no prophylactic vaccine is available as of yet. DNA-based immunization is a promising modality to generate cellular and ...

    Abstract BACKGROUND: Vaccination against HCV is an effective measure in reduction of virus-related public health burden and mortality. However, no prophylactic vaccine is available as of yet. DNA-based immunization is a promising modality to generate cellular and humoral immune responses. The objective of this study is to provide a systematic review of HCV DNA vaccines and investigate and discuss the strategies employed to optimize their efficacies. METHODS: MEDLINE (PubMed), Web of Science, Scopus, ScienceDirect, and databases in persian language including the Regional Information Centre for Science & Technology (RICeST), the Scientific Information Database and the Iranian Research Institute for Information Science and Technology (IranDoc) were examined to identify studies pertaining to HCV nucleic acid vaccine development from 2000 to 2020. RESULTS: Twenty-seven articles were included. Studies related to HCV RNA vaccines were yet to be published. A variety of strategies were identified with the potential to optimize HCV DNA vaccines such as incorporating multiple viral proteins and molecular tags such as HBsAg and Immunoglobulin Fc, multi-epitope expression, co-expression plasmid utilization, recombinant subunit immunogens, heterologous prime-boosting, incorporating NS3 mutants in DNA vaccines, utilization of adjuvants, employment of less explored methods such as Gene Electro Transfer, construction of multi- CTL epitopes, utilizing co/post translational modifications and polycistronic genes, among others. The effectiveness of the aforementioned strategies in boosting immune response and improving vaccine potency was assessed. CONCLUSIONS: The recent progress on HCV vaccine development was examined in this systematic review to identify candidates with most promising prophylactic and therapeutic potential.
    Keywords Hepatitis C virus ; RNA ; databases ; epitopes ; genes ; immune response ; immunoglobulins ; mortality ; plasmids ; public health ; recombinant vaccines ; research institutions ; systematic review ; vaccination ; vaccine development ; virology
    Language English
    Dates of publication 2021-12
    Size p. 248.
    Publishing place BioMed Central
    Document type Article
    ZDB-ID 2160640-7
    ISSN 1743-422X
    ISSN 1743-422X
    DOI 10.1186/s12985-021-01716-8
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Hepatitis C virus DNA vaccines: a systematic review.

    Shayeghpour, Ali / Kianfar, Roya / Hosseini, Parastoo / Ajorloo, Mehdi / Aghajanian, Sepehr / Hedayat Yaghoobi, Mojtaba / Hashempour, Tayebeh / Mozhgani, Sayed-Hamidreza

    Virology journal

    2021  Volume 18, Issue 1, Page(s) 248

    Abstract: Background: Vaccination against HCV is an effective measure in reduction of virus-related public health burden and mortality. However, no prophylactic vaccine is available as of yet. DNA-based immunization is a promising modality to generate cellular ... ...

    Abstract Background: Vaccination against HCV is an effective measure in reduction of virus-related public health burden and mortality. However, no prophylactic vaccine is available as of yet. DNA-based immunization is a promising modality to generate cellular and humoral immune responses. The objective of this study is to provide a systematic review of HCV DNA vaccines and investigate and discuss the strategies employed to optimize their efficacies.
    Methods: MEDLINE (PubMed), Web of Science, Scopus, ScienceDirect, and databases in persian language including the Regional Information Centre for Science & Technology (RICeST), the Scientific Information Database and the Iranian Research Institute for Information Science and Technology (IranDoc) were examined to identify studies pertaining to HCV nucleic acid vaccine development from 2000 to 2020.
    Results: Twenty-seven articles were included. Studies related to HCV RNA vaccines were yet to be published. A variety of strategies were identified with the potential to optimize HCV DNA vaccines such as incorporating multiple viral proteins and molecular tags such as HBsAg and Immunoglobulin Fc, multi-epitope expression, co-expression plasmid utilization, recombinant subunit immunogens, heterologous prime-boosting, incorporating NS3 mutants in DNA vaccines, utilization of adjuvants, employment of less explored methods such as Gene Electro Transfer, construction of multi- CTL epitopes, utilizing co/post translational modifications and polycistronic genes, among others. The effectiveness of the aforementioned strategies in boosting immune response and improving vaccine potency was assessed.
    Conclusions: The recent progress on HCV vaccine development was examined in this systematic review to identify candidates with most promising prophylactic and therapeutic potential.
    MeSH term(s) Animals ; Hepacivirus/genetics ; Hepatitis C ; Humans ; Iran ; Mice ; Mice, Inbred BALB C ; Vaccines, DNA/genetics ; Viral Hepatitis Vaccines/genetics
    Chemical Substances Vaccines, DNA ; Viral Hepatitis Vaccines
    Language English
    Publishing date 2021-12-13
    Publishing country England
    Document type Journal Article ; Systematic Review
    ZDB-ID 2160640-7
    ISSN 1743-422X ; 1743-422X
    ISSN (online) 1743-422X
    ISSN 1743-422X
    DOI 10.1186/s12985-021-01716-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top